Current Report Filing (8-k)
May 28 2021 - 6:15AM
Edgar (US Regulatory)
0001356090
false
0001356090
2021-05-24
2021-05-24
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 24, 2021
PRECIGEN, INC.
(Exact name of registrant as specified in its
charter)
|
|
|
|
|
Virginia
|
|
001-36042
|
|
26-0084895
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
20374 Seneca Meadows Parkway, Germantown, Maryland
20876
(Address of principal executive offices) (Zip
Code)
(301) 556-9900
(Registrant’s telephone number, including
area code)
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
☐
|
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, No Par Value
|
|
PGEN
|
|
Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
|
Item 5.02
|
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
|
As previously announced, Precigen, Inc. (the “Company”)
is currently conducting an executive search process to identify a new Chief Financial Officer with the qualifications to contribute to
the Company’s growth from a clinical stage company to a commercial organization. On May 24, 2021, the Company accepted D. Bradford
Osborne’s resignation from his position of Vice President, Finance and Accounting and interim principal accounting officer to pursue
a new opportunity. Mr. Osborne and the Company have agreed that the resignation will be effective June 10, 2021.
Effective June 10, 2021, the Company will appoint
James V. Lambert (age 56), currently the Executive Director, Finance for PGEN Therapeutics, Inc., a wholly owned subsidiary of the Company
(“PGEN Therapeutics”), to serve as principal accounting officer for an interim period while the Company continues its search
for a new Chief Financial Officer. Mr. Lambert joined PGEN Therapeutics in June 2017 in connection with the acquisition of GenVec, Inc.
and has since served in the role of Executive Director, Finance. From 2014 to 2017 Mr. Lambert served in the positions of GenVec’s
Senior Director and then Vice President, Accounting and Finance, Corporate Controller and Treasurer. During this period Mr. Lambert also
served as GenVec’s principal financial officer and principal accounting officer. There are no arrangements or understandings between
Mr. Lambert and any other persons pursuant to which he was selected as an officer of the Company, and Mr. Lambert is not related to any
other executive officer or director of the Company. Mr. Lambert has no direct or indirect material interest in any transaction required
to be disclosed pursuant to Item 404(a) of Regulation S-K. There will not be any changes to Mr. Lambert’s compensation arrangements
in connection with his interim appointment.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
Precigen, Inc.
|
|
|
|
|
|
|
By:
|
|
/s/ Donald P. Lehr
|
|
|
|
|
Donald P. Lehr
|
|
|
|
|
Chief Legal Officer
|
|
Dated: May 27, 2021
Precigen (NASDAQ:PGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Precigen (NASDAQ:PGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024